<SEC-DOCUMENT>0001453687-25-000087.txt : 20250508
<SEC-HEADER>0001453687-25-000087.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508071314
ACCESSION NUMBER:		0001453687-25-000087
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508
EFFECTIVENESS DATE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cartesian Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-287062
		FILM NUMBER:		25923834

	BUSINESS ADDRESS:	
		STREET 1:		7495 NEW HORIZON WAY
		CITY:			FREDERICK
		STATE:			MD
		ZIP:			21703
		BUSINESS PHONE:		301-348-8698

	MAIL ADDRESS:	
		STREET 1:		7495 NEW HORIZON WAY
		CITY:			FREDERICK
		STATE:			MD
		ZIP:			21703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SELECTA BIOSCIENCES INC
		DATE OF NAME CHANGE:	20090109
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>rnacs-8may82025.htm
<DESCRIPTION>S-8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i72bdcd5b20a5488291f1d6d629400869_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As filed with the Securities and Exchange Commission on May 8, 2025</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registration No. 333-_____</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.780%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM S-8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGISTRATION STATEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UNDER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">THE SECURITIES ACT OF 1933</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CARTESIAN THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26-1622110</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction<br>of incorporation or organization)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer<br>Identification No.)</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7495 New Horizon Way<br>Frederick, Maryland</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21703</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip code)</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(301) 348-8698</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Telephone number, including area code, of registrant's principal executive offices)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cartesian Therapeutics, Inc. Amended and Restated 2016 Incentive Award Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cartesian Therapeutics, Inc. Amended and Restated 2018 Employment Inducement Incentive Award Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Full title of the plan)</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carsten Brunn, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cartesian Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7495 New Horizon Way</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Frederick, Maryland 21703</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Copy to&#58;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Brian K. Rosenzweig</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Sarah C. Griffiths</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Covington &#38; Burling LLP</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">One International Place, Suite 1020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Boston, Massachusetts 02110</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(617) 603-8805</font></div><div style="margin-top:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 under the Exchange Act.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">   </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.188%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPLANATORY NOTE</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This registration statement on Form S-8 (the &#8220;Registration Statement&#8221;) is being filed for the purpose of registering an additional 1,030,694 shares of common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), of Cartesian Therapeutics, Inc. (the &#8220;Registrant&#8221;) to be issued pursuant to the Registrant&#8217;s Amended and Restated 2016 Incentive Award Plan (the &#8220;Incentive Plan&#8221;) and an additional 450,000 shares of the Registrant&#8217;s Common Stock to be issued pursuant to the Registrant&#8217;s Amended and Restated 2018 Employment Inducement Incentive Award Plan (the &#8220;Inducement Plan&#8221;).</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</font></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Incorporation of Documents by Reference</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following documents filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) pursuant to the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), are hereby incorporated by reference into this registration statement&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Registrant&#8217;s definitive proxy statement on Schedule 14A for the 2025 annual meeting of stockholders, filed with the Commission on </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368725000075/rnac-20250428.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">April 2</a><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368725000075/rnac-20250428.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">8</a><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368725000075/rnac-20250428.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">, 202</a><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368725000075/rnac-20250428.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001453687/000145368725000060/rnac-20241231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 13, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368725000085/rnac-20250331.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">May </a><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368725000085/rnac-20250331.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">8</a><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368725000085/rnac-20250331.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">, 202</a><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368725000085/rnac-20250331.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The Registrant&#8217;s Current Reports on Form 8-K filed with the Commission on </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368725000050/rnac-20250127.htm" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">January 27, 2025</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368725000064/rnac-20250408.htm" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">April 8, 2025</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368725000077/rnac-20250429.htm" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">April </a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368725000077/rnac-20250429.htm" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">29</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368725000077/rnac-20250429.htm" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">, 2025</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (except for Item 7.01 and Exhibits 99.1 and 99.2 thereto)&#59; an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The description of the Registrant&#8217;s Common Stock contained in Exhibit 4.12 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the Commission on </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368725000060/exhibit412descriptionofsec.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 13, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and any amendment or report filed with the Commission for the purpose of updating such description&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Registrant&#8217;s Registration Statements on Form S-8 (File Nos. </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000110465916129190/a15-22910_14s8.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">333-212215</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368718000018/selectabiosciencess-8_apri.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">333-224109</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368718000081/selectabiosciencess-8_nove.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">333-228264</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368719000036/selectabiosciencess-8_marc.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">333-230501</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368720000058/selectabiosciencess-8_june.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">333-239075</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368721000070/selectabiosciences_s8-2021.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">333-256061</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368722000088/selectabiosciences_s8-2022.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">333-264691</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523214712/d642337ds8.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">333-274036</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000114036124002120/ny20014884x3_s8.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">333-276486</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000126/rnacs-8november72024.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">333-283049</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) filed with the Securities and Exchange Commission, relating to the Incentive Plan and the Inducement Plan.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed incorporated herein by reference shall be deemed to be modified or superseded for the purpose of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is, or is deemed to be, incorporated herein by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i72bdcd5b20a5488291f1d6d629400869_4"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 8. Exhibits</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000110465916129891/a16-14002_1ex3d1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3.1</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-37798) filed on June 29, 2016).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368722000109/exhibit31_charteramendment.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3.2</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-37798) filed on June 21, 2022).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex33.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3.3</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.3 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-37798) filed on November 13, 2023).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368724000048/exhibit32certificateofamen.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3.4</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-37798) filed on March 28, 2024).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523276086/d549858dex32.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3.5</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated By-laws of the Registrant (incorporated herein by reference to Exhibit 3.2 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-37798) filed on November 13, 2023).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368725000060/exhibit41rnacspecimensto.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">4.1</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specimen Stock Certificate evidencing the shares of common stock (incorporated herein by reference to Exhibit 4.1 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-37798) filed on March 13, 2025.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="exhibit51_opinion-covingto.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">5.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opinion of Covington &#38; Burling LLP.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="exhibit231_consent-eyllpxs.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">23.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Ernst &#38; Young LLP, the Registrant's independent registered public accounting firm.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="exhibit51_opinion-covingto.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">23.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Covington &#38; Burling LLP (included in Exhibit 5.1).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney (included on the signature pages of this Registration Statement).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0001453687/000114036124035433/ny20033174x1_ex10-1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">99.1</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cartesian Therapeutics, Inc. Amended and Restated 2016 Incentive Award Plan, and forms of award agreements thereunder (incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-281204) filed on August 2, 2024).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0001453687/000145368725000060/exhibit103_employmentinduc.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">99.2</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cartesian Therapeutics, Inc. Amended and Restated 2018 Employment Inducement Incentive Award Plan, and forms of award agreements thereunder (incorporated herein by reference to Exhibit 10.3 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-37798) filed on March 13, 2025).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="exhibit1071_s-82025.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">107.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filing fee table.</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Filed herewith</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i72bdcd5b20a5488291f1d6d629400869_7"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="margin-top:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Frederick, State of Maryland, as of May 8, 2025.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CARTESIAN THERAPEUTICS, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Carsten Brunn, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer, and Director</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the undersigned officers and directors of the registrant hereby severally constitutes and appoints Carsten Brunn, Ph.D. and Blaine Davis, and each of them singly (with full power to each of them to act alone), as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for him or her and in his or her name, place and stead, and in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this registration statement and any other registration statement for the same offering that is to be effective under Rule 462(b) of the Securities Act of 1933, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:46.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.638%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Carsten Brunn, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer, and Director</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Blaine Davis</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blaine Davis</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Carrie S. Cox</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrie S. Cox</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Timothy C. Barabe</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy C. Barabe</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nishan de Silva, M.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nishan de Silva, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Murat Kalayoglu, M.D. Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Murat Kalayoglu, M.D. Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kemal Malik, MBBS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kemal Malik, MBBS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Singer, M.D. Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Singer, M.D. Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Timothy Springer, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Springer, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Patrick Zenner</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patrick Zenner</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>exhibit1071_s-82025.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="idd4feae2bd3046b0a6f640b680cdfb3c_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 107.1</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALCULATION OF FILING FEE TABLE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form S-8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Form Type)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cartesian Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table 1 - Newly Registered Securities</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security Type</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security Class Title</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fee Calculation Rule</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">to be</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Proposed<br>Maximum<br>Offering Price<br>Per Share</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Proposed<br>Maximum<br>Aggregate<br>Offering Price</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fee Rate</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of<br>Registration<br>Fee</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Common Stock, par value $0.0001 per share, to be issued under the Registrant&#8217;s Amended and Restated 2016 Incentive Award Plan</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rules 457(c) and 457(h)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030,694&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.48 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12,863,061.12</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$153.10 per $1,000,000</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,969.33</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Common Stock, par value $0.0001 per share, to be issued under the Registrant&#8217;s Amended and Restated 2018 Employment Inducement Award Plan</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rules 457(c) and 457(h)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.48 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,616,000.00</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$153.10 per $1,000,000</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$859.81</font></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Offering Amounts</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18,479,061.12</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,829.14</font></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Fee Offsets </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</font></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Fee Due</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,829.14</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">In accordance with Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this registration statement (this &#8220;Registration Statement&#8221;) shall be deemed to cover any additional securities that may from time to time be offered or issued under the Cartesian Therapeutics, Inc. Amended and Restated 2016 Incentive Award Plan (the &#8220;Incentive Plan&#8221;) and the Cartesian Therapeutics, Inc. Amended and Restated 2018 Employment Inducement Incentive Award Plan (the &#8220;Inducement Plan&#8221;) to prevent dilution resulting from stock splits, stock dividends or similar transactions. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Consists of 1,030,694 shares of the Registrant&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) that may become issuable under the Incentive Plan pursuant to its terms.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act and based upon the average of the high and low prices of the Registrant&#8217;s Common Stock as reported on the Nasdaq Global Market on May 2, 2025.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Consists of 450,000 shares of Common Stock that may become issuable under the Inducement Plan pursuant to its terms.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Registrant does not have any fee offsets.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>exhibit51_opinion-covingto.htm
<DESCRIPTION>EX-5.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i19a86ce2e0c24c9c9e2f66df492221c9_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 5.1</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><img alt="covingtonlogo.jpg" src="covingtonlogo.jpg" style="height:97px;margin-bottom:5pt;vertical-align:text-bottom;width:606px"></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">May 8, 2025</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cartesian Therapeutics, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7495 New Horizon Way</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Frederick, MD 21703</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have acted as counsel to Cartesian Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), in connection with the registration by the Company under the Securities Act of 1933, as amended (the &#8220;Act&#8221;), of 1,484,694 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;), issuable under the Company&#8217;s Amended and Restated 2016 Incentive Award Plan (the &#8220;Incentive Plan&#8221;) and under the Company&#8217;s Amended and Restated 2018 Employment Inducement Incentive Award Plan (the &#8220;Inducement Plan&#8221;), pursuant to the registration statement on Form S-8 being filed with the Securities and Exchange Commission on the date hereof (such registration statement is referred to herein as the &#8220;Registration Statement&#8221;).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have reviewed such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion. We have assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have relied as to certain matters on information obtained from public officials, officers of the Company and other sources believed by us to be responsible.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based upon the foregoing, we are of the opinion that the Shares have been duly authorized and, when issued and paid for in accordance with the terms of the Company&#8217;s Restated Certificate of Incorporation, as amended, the Incentive Plan or the Inducement Plan, as the case may be, and any individual agreements relating to such Shares, will be validly issued, fully paid and nonassessable.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are members of the bar of the State of New York. We do not express any opinion herein on any laws other than the General Corporation Law of the State of Delaware and reported judicial decisions interpreting such law.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-top:6pt;padding-left:144pt;padding-right:144pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Very truly yours,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Covington &#38; Burling LLP</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit231_consent-eyllpxs.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="idb914e0dcb31481283274bbd61ba0c05_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Cartesian Therapeutics, Inc. Amended and Restated 2016 Incentive Award Plan and Cartesian Therapeutics, Inc. Amended and Restated 2018 Employment Inducement Incentive Award Plan of our report dated March 13, 2025, with respect to the consolidated financial statements of Cartesian Therapeutics, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Ernst &#38; Young LLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 8, 2025</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>covingtonlogo.jpg
<TEXT>
begin 644 covingtonlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !A EX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?P/UR>U3S+F*^NGB3^\X@B('YXK'_9N\%Z!XH\ ZYXJU31[7Q=XFENIVDBU
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MT^3)YWEXV*?X\@\$9S6O9^/M-OK47$,=RT1^Q%6,84D73*L1P3D8W#=GI[T
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MTHY;D<+D9SBK/C+6-2\.7=KJ=NSW6EPQR/J%BL:L_E J#-&0-Q9-V2N2&4$
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MW&C7,:W6IPWTD%LLLU[!#^XNC,HE,*J &C"%CSD8"X/WJZ[P3<:Y<6FH-K\
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M28PQ3%4)=;A?ED_[=W'([HW<UTWC*WUIK2S?0[IH)_.6WF'EB0>5(0C2X/\
M%'D..WRD$'/ !LPZ;;6]]<WL<>VYN%1)9-Q.X)NVC&<#&X]/6K5<+ ?$4?C+
MRVDU!K9;O:%9(_L9L_)^]NQN\SS/?.>VSFL+0F^(<?AR43@G5V33GA6\D#Q[
MF;_2&9EC4J,<-'AMNWAOFR #U>BLGPK)=R>'K%K\7"WWE_Z0+H+YGF9.[[HV
MXSG&.,8Q6M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[4/%&E:3:WUS>7L=M;V4J07$DF0(W8(5!^HD3_OJL76/AO9:U?:S<S7=RO\
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M9<?>7[H/7;@'.!@ ZNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,_6K"YU&WACMKF.U*SQRLTD)DW*CAMH&Y<9('/-<BGPCLK?6GO[:[:.
M-+Q+VULY(@\-NVR99$"YY1C<2-CC:QX..*WO' NH_#M[>6M[+9O9V\]QB(#,
MA$3[02>@#$-QU*CMD%?! NI?#MC>75[+=M>6T%P1+C*,8EW 'T)RV.Q)[8
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M^S[7^TMNS[9Y*^;C&,;\9Z<5>HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
